Anne Dejean-Assémat (born 6 January, 1957) is a French molecular biologist working on the mechanisms leading to the development of human cancers.

Anne Dejean-Assémat was educated at the Pierre and Marie Curie University in Paris, graduating with a Master of Science degree in Genetics in 1980.

[4][5] Together with Hugues de Thé, she then discovered the PML-RARa oncoprotein as the genetic defect responsible for acute promyelocytic leukemia (APL) and elucidated its oncogenic properties.

[6][7] Dejean-Assémat's further work led to the characterization of the mechanisms underlying the cure of APL by retinoic acid  and arsenic, a treatment developed in China and that remains the most efficient oncogene-targeted therapy  described so far.

[10] Dejean-Assémat's laboratory next contributed to the emergence of the SUMO field by unveiling an as yet unanticipated function for this pathway as a major epigenetic determinant of gene expression regulation, with a key role in the repression of  innate immunity[11] and the maintenance of cell identity.